ClinicalTrials.gg
RecruitingNCT07759362Updated Nov 12, 2026

Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)

A Phase 3 interventional study of KN3835 and Placebo in Flexible Hammertoe and Semi-flexible Hammertoe, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Recruiting at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 12, 202618 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.

02

Conditions studied

  • Flexible Hammertoe
  • Semi-flexible Hammertoe
03

In context

Lead sponsor

Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations.
  • If female, be of non- or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective when with a male partner for the duration of the study and for 28 days after treatment.
  • Be willing and able to comply with all protocol required visits and assessments.

Key Exclusion Criteria:

  • Has any musculoskeletal, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain.
  • Has any significant medical condition(s), which in the investigator's opinion would make the participant unsuitable for enrollment in the study.
  • Has previously participated in clinical studies of KN3835 for plantar fasciitis, plantar fibromatosis, or HMT.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
554 participants (estimated)

Study arms

  • Experimental
    KN3835

    Biological: KN3835

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalKN3835

    Participants will receive KN3835.

    Also known as: EN3835

  • OtherPlacebo

    Participants will receive placebo matching to KN3835.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 57 in Flexion Contracture as Measured by Goniometer

    Time frame: Baseline, Day 57

Secondary outcomes

  1. Change From Baseline to Day 57 in the Foot Function Index (FFI) Difficulty Subscale Score

    Time frame: Baseline, Day 57

  2. Change From Baseline to Day 57 in the FFI Activity Limitation Subscale Score

    Time frame: Baseline, Day 57

  3. Change From Baseline to Day 57 in the Patient Global Impression of Severity (PGIS) HMT Overall Scale Score

    Time frame: Baseline, Day 57

  4. Change From Baseline up to Day 57 in Flexion Contracture as Measured by Goniometer

    Time frame: Baseline, up to Day 57

  5. Percent Change From Baseline up to Day 57 in Flexion Contracture as Measured by Goniometer

    Time frame: Baseline, up to Day 57

  6. Change From Baseline up to Day 57 in the FFI Pain Subscale Score

    Time frame: Baseline, up to Day 57

  7. Change From Baseline up to Day 57 in the FFI Difficulty Subscale Score

    Time frame: Baseline, up to Day 57

  8. Change from Baseline up to Day 57 in the FFI Activity Limitation Subscale Score

    Time frame: Baseline, up to Day 57

  9. Change from Baseline up to Day 57 in the FFI Total score

    Time frame: Baseline, up to Day 57

  10. Change from Baseline up to Day 57 in the PGIS Foot Pain Subscale Score

    Time frame: Baseline, up to Day 57

  11. Change from Baseline up to Day 57 in the PGIS Difficulty Subscale Score

    Time frame: Baseline, up to Day 57

  12. Change from Baseline up to Day 57 in the PGIS Activity Limitation Subscale Score

    Time frame: Baseline, up to Day 57

  13. Change from Baseline up to Day 57 in the PGIS HMT Overall Scale Score

    Time frame: Baseline, up to Day 57

  14. Number of Participants With >=1 Point Improvement in the Foot Patient Global Impression of Change (PGIC) Foot Pain Subscale Score

    Time frame: Up to Day 57

  15. Number of Participants With >=1 Point Improvement in the PGIC Difficulty Subscale Score

    Time frame: Up to Day 57

  16. Number of Participants With >=1 Point Improvement in the PGIC Activity Limitation Subscale Score

    Time frame: Up to Day 57

  17. Number of Participants With >=1 Point Improvement in the PGIC HMT Overall Scale Score

    Time frame: Up to Day 57

  18. Change from Baseline in the Pain Intensity Numeric Rating Scale (NRS) Score

    Time frame: Up to Day 57

  19. Number of Participants With >=1 Point Improvement in the Clinician Global Impression of Change (CGIC) Scale Score

    Time frame: Up to Day 57

  20. Number of Participants With >=1 Point Improvement in the Subject Satisfaction with Treatment Scale

    Time frame: Up to Day 57

  21. Number of Participants With a ≥ 30% reduction in Flexion Contracture as measured by Goniometry

    Time frame: Baseline to Day 57

  22. Number of Participants With a ≥ 50% reduction in Flexion Contracture as measured by Goniometry

    Time frame: Baseline to Day 57

  23. Number of Participants With TEAEs

    Time frame: Baseline to Day 57

07

Study locations

25 of 25 sites recruiting
  • Keenova Site-010
    Tucson, Arizona 85712, United States
    Recruiting
    • Nebojsa Skrepnik · Principal investigator
  • Keenova Site-009
    Corona, California 92882, United States
    Recruiting
    • Babak Alavynejad · Principal investigator
  • Keenova Site-005
    Encinitas, California 92024, United States
    Recruiting
    • Ryan Meineke · Principal investigator
  • Keenova Site-015
    Los Angeles, California 90010, United States
    Recruiting
    • Felix Sigal · Principal investigator
  • Keenova Site-021
    Los Angeles, California 90063, United States
    Recruiting
    • Charles Ananian · Principal investigator
  • Keenova Site-022
    Los Angeles, California 93710, United States
    Recruiting
    • Shawn Cazzel · Principal investigator
  • Keenova Site-008
    Tarzana, California 91356, United States
    Recruiting
    • Fardin Hakakian · Principal investigator
  • Keenova Site-016
    Medley, Florida 33166, United States
    Recruiting
    • Nelson Gonzalez · Principal investigator
  • Keenova Site-011
    Miami, Florida 33156, United States
    Recruiting
    • Maria Surprenant · Principal investigator
  • Keenova Site-013
    Miami, Florida 33184, United States
    Recruiting
    • Rogelio Oscar Bardinas Rodriguez · Principal investigator
  • Keenova Site-004
    Pinellas Park, Florida 33782, United States
    Recruiting
    • Jason Levy · Principal investigator
  • Keenova Site-007
    Sweetwater, Florida 33172, United States
    Recruiting
    • Edward Gonzalez · Principal investigator
  • Keenova Site-023
    Springfield, Illinois 62704, United States
    Recruiting
    • John Sigle · Principal investigator
  • Keenova Site-020
    Overland Park, Kansas 66211, United States
    Recruiting
    • Atul Patel · Principal investigator
  • Keenova Site-025
    Westwood, New Jersey 07675, United States
    Recruiting
    • Vincent Giacalone · Principal investigator
  • Keenova Site-003
    Bedford, Texas 76021, United States
    Recruiting
    • Howard Harris · Principal investigator
  • Keenova Site-014
    Fort Worth, Texas 76104, United States
    Recruiting
    • Lena Levine · Principal investigator
  • Keenova Site-019
    Georgetown, Texas 78628, United States
    Recruiting
    • Brent Wood · Principal investigator
  • Keenova Site-017
    Houston, Texas 77027, United States
    Recruiting
    • Gabriel Maislos · Principal investigator
  • Keenova Site-001
    McAllen, Texas 78501, United States
    Recruiting
    • Joseph Caporusso · Principal investigator
  • Keenova Site-002
    McAllen, Texas 78501, United States
    Recruiting
    • Joseph Caporusso · Principal investigator
  • Keenova Site-024
    San Antonio, Texas 78251, United States
    Recruiting
    • Robert Farber · Principal investigator
  • Keenova Site-018
    San Antonio, Texas 78258, United States
    Recruiting
    • Steven Kissel · Principal investigator
  • Keenova Site-012
    Bountiful, Utah 84010, United States
    Recruiting
    • Richard Seegmiller · Principal investigator
  • Keenova Site-006
    Salt Lake City, Utah 84107, United States
    Recruiting
    • Clark Larsen · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2026
First posted
Aug 12, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added
Show 18 added (18 United States)
  • Keenova Site-010 · Tucson, United States
  • Keenova Site-005 · Encinitas, United States
  • Keenova Site-015 · Los Angeles, United States
  • Keenova Site-021 · Los Angeles, United States
  • Keenova Site-022 · Los Angeles, United States
  • Keenova Site-016 · Medley, United States
  • Keenova Site-011 · Miami, United States
  • Keenova Site-013 · Miami, United States
  • Keenova Site-023 · Springfield, United States
  • Keenova Site-020 · Overland Park, United States
  • Keenova Site-025 · Westwood, United States
  • Keenova Site-014 · Fort Worth, United States
  • Keenova Site-019 · Georgetown, United States
  • Keenova Site-017 · Houston, United States
  • Keenova Site-001 · McAllen, United States
  • Keenova Site-024 · San Antonio, United States
  • Keenova Site-018 · San Antonio, United States
  • Keenova Site-012 · Bountiful, United States
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    18 sites added
    Show 18 added (18 United States)
    • Keenova Site-010 · Tucson, United States
    • Keenova Site-005 · Encinitas, United States
    • Keenova Site-015 · Los Angeles, United States
    • Keenova Site-021 · Los Angeles, United States
    • Keenova Site-022 · Los Angeles, United States
    • Keenova Site-016 · Medley, United States
    • Keenova Site-011 · Miami, United States
    • Keenova Site-013 · Miami, United States
    • Keenova Site-023 · Springfield, United States
    • Keenova Site-020 · Overland Park, United States
    • Keenova Site-025 · Westwood, United States
    • Keenova Site-014 · Fort Worth, United States
    • Keenova Site-019 · Georgetown, United States
    • Keenova Site-017 · Houston, United States
    • Keenova Site-001 · McAllen, United States
    • Keenova Site-024 · San Antonio, United States
    • Keenova Site-018 · San Antonio, United States
    • Keenova Site-012 · Bountiful, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07759362
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Aug 11, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Operations
Contact
clinicaltrials@endo.com
800-462-3636
Medical Director, MD
study director · Endo USA Inc., a Keenova Therapeutics Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion